ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses2.75 M1.7 M1.92 M1.96 M1.74 M7.32 MResearch & development1.09 M1.01 M678 K1.47 M1.42 M4.57 MOperating income3.84 M7.1 M2.6 M3.42 M3.16 M16.28 MNon-Operating Income, Total36 K281 K68 K12 K23 K384 KInterest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses36 K281 K68 K12 K23 K384 KUnusual income/expense——————Pretax income-3.88 M-6.75 M-2.53 M-3.43 M-3.13 M-15.85 MEquity in earnings——————Taxes7 000—2 0004 0000—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations3.88 M6.74 M2.53 M3.44 M3.13 M15.84 MDiscontinued operations——————Net income3.88 M6.74 M2.53 M3.44 M3.13 M15.84 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders3.88 M6.74 M2.53 M3.44 M3.13 M15.84 MBasic earnings per share (Basic EPS)-3.39-5.17-1.92-2.6-2.36-12.05Diluted earnings per share (Diluted EPS)-3.39-5.17-1.92-2.6-2.36-12.05Average basic shares outstanding1.1 M1.16 M1.32 M1.32 M1.32 M5.13 MDiluted shares outstanding1.1 M1.16 M1.32 M1.32 M1.32 M5.13 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)6 0004 0005 0006 0006 00021 K
Galecto Inc
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.